Nadofaragene: a new era of precision medicine for bladder cancer-Reference-Cited by-同舟云学术

Nadofaragene: a new era of precision medicine for bladder cancer

Published:2023-11-07 Issue:1 Volume:86 Page:7-10
ISSN:2049-0801
Container-title:Annals of Medicine & Surgery
language:en
Short-container-title:

Author:

Zehra Maha¹,Fatima Tehreem¹,Hanif Areeba²,Raufi Nahid³,Khan Afsheen¹

Affiliation:

1. Department of Medicine, Dow University of Health Sciences

2. Dow University of Health Sciences, Karachi, Pakistan

3. Department of Medicine, Kabul Medical University, Afghanistan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,Surgery

Reference16 articles.

1. Systemic therapy for advanced urothelial carcinoma: current standards and treatment considerations;Dietrich;Am Soc Clin Oncol Educ Book,2018

2. Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval;Martini;Front Immunol,2023

3. The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: a summary from the institute for clinical and economic review’s midwest comparative effectiveness public advisory council;Beinfeld;J Manag Care Spec Pharm,2021

4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial;Boorjian;Lancet Oncol,2021

5. Nadofaragene firadenovec: first approval;Lee;Drugs,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling FDA-Approved Drugs and Formulations in the Management of Bladder Cancer: A Review;Current Pharmaceutical Biotechnology;2024-05-23